Mirum Pharmaceuticals, Inc.
MIRM
$71.81
$0.290.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 62.33% | 69.31% | 80.76% | 112.14% | 128.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 62.33% | 69.31% | 80.76% | 112.14% | 128.34% |
| Cost of Revenue | 22.81% | 44.98% | 73.56% | 216.38% | 281.46% |
| Gross Profit | 77.49% | 78.19% | 83.19% | 88.77% | 97.87% |
| SG&A Expenses | 28.62% | 32.85% | 38.62% | 51.85% | 58.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.43% | 37.03% | 43.64% | 57.76% | 59.15% |
| Operating Income | 47.36% | 29.64% | 19.74% | 13.33% | 8.47% |
| Income Before Tax | 46.61% | 51.70% | 46.49% | 39.99% | 38.83% |
| Income Tax Expenses | -30.64% | 1.49% | 3.94% | 102.10% | 158.66% |
| Earnings from Continuing Operations | 46.35% | 51.22% | 46.18% | 39.21% | 38.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.35% | 51.22% | 46.18% | 39.21% | 38.08% |
| EBIT | 47.36% | 29.64% | 19.74% | 13.33% | 8.47% |
| EBITDA | 62.98% | 43.95% | 34.93% | 30.03% | 21.79% |
| EPS Basic | 51.46% | 58.75% | 55.62% | 49.23% | 48.23% |
| Normalized Basic EPS | 5.94% | -13.12% | -9.66% | 67.85% | 64.14% |
| EPS Diluted | 51.52% | 58.78% | 55.66% | 49.34% | 48.34% |
| Normalized Diluted EPS | 5.94% | -13.12% | -9.66% | 67.80% | 64.09% |
| Average Basic Shares Outstanding | 10.09% | 14.62% | 20.09% | 21.30% | 21.86% |
| Average Diluted Shares Outstanding | 10.09% | 14.62% | 20.09% | 21.19% | 21.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |